Patrick D. Yeramian - May 15, 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Chief Medical Officer
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol
AMLX
Transactions as of
May 15, 2023
Transactions value $
-$279,368
Form type
4
Date filed
5/17/2023, 04:58 PM
Previous filing
Apr 19, 2023
Next filing
Jan 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Options Exercise $814 +2.2K +1.06% $0.37* 211K May 15, 2023 Direct F1
transaction AMLX Common Stock Options Exercise $67.2K +9.76K +4.64% $6.88 220K May 15, 2023 Direct F1
transaction AMLX Common Stock Sale -$347K -12K -5.43% $29.03 208K May 15, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (right to buy) Options Exercise $0 -2.2K -12.5% $0.00 15.4K May 15, 2023 Common Stock 2.2K $0.37 Direct F1, F3
transaction AMLX Stock Option (right to buy) Options Exercise $0 -9.76K -22.43% $0.00 33.8K May 15, 2023 Common Stock 9.76K $6.88 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.00 to $29.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 As of the date of this filing, 2,201 shares subject to the option are vested and exercisable. 15,404 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023.
F4 As of the date of this filing, 13,746 shares subject to the option are vested and exercisable. 23,600 shares subject to such option vest and become exercisable in substantially equal monthly installments until December 19, 2023.